

REMARKS

The communication mailed October 3, 2003 has been received and reviewed. Claims 1 through 20 are pending in the application. The application is to be amended as previously set forth. All amendments are made without prejudice or disclaimer.

Pursuant to 35 U.S.C. § 121, applicants were required to elect a single disclosed species to which the claims shall be restricted if no generic claim is finally held to be patentable. Claims 1 and 16 were stated to be generic with respect to the member of the specific binding pair.

Applicants elect Fc receptors as the immunoglobulin binding moiety without traverse. All claims are believed to readable thereon.

In view of the foregoing, the application should now be in condition for examination on the merits. If the foregoing should raise any questions, the Office is kindly requested to contact applicants' undersigned representative at the address or telephone number given herein.

Respectfully submitted,



Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922»

Date: October 18, 2003